Lorigerlimab

Names

[ Name ]:
Lorigerlimab

Biological Activity

[Description]:

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

[In Vitro]

Lorigerlimab (0.01 nM-1 nM) 与 Jurkat/PD-1 细胞结合并阻断 PD-L1 与细胞结合[2]。 Lorigerlimab 可以独立地参与和阻断表达一种或另一种检查点分子的细胞上的 PD-1 和 CTLA-4 (EC50: PD-1+ 细胞为 0.42 nM，CTLA-4+ 细胞为 4.8 nM, PD-1 和 CTLA-4+ 细胞为 0.013 nM)[2]。

[In Vivo]

Lorigerlimab (75 mg/kg，静脉注射) 在食蟹猴中显示出 CTLA-4 阻断作用[2]。 Lorigerlimab (10-100 mg/kg，静脉注射，4 周) 在食蟹猴中耐受性良好，半衰期约为 7 天[2]。 Animal Model: Cynomolgus monkeys [4] Dosage: 75 mg/kg Administration: i.v. Result: Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen.

[References]

[1]. Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155.

[2]. Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.

[3]. Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.